Clorox (NYSE:CLX) Earns Underperform Rating from Analysts at BNP Paribas

BNP Paribas initiated coverage on shares of Clorox (NYSE:CLX) in a research note published on Monday morning, Marketbeat reports. The brokerage issued an underperform rating and a $130.00 target price on the stock.

CLX has been the topic of a number of other research reports. Wells Fargo & Company dropped their price target on shares of Clorox from $140.00 to $135.00 and set an underweight rating on the stock in a research report on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Clorox from $155.00 to $151.00 and set a hold rating on the stock in a research report on Wednesday, April 17th. Argus raised shares of Clorox to a hold rating in a research report on Tuesday, June 4th. DA Davidson reissued a neutral rating and issued a $162.00 price target on shares of Clorox in a research report on Wednesday, April 17th. Finally, The Goldman Sachs Group initiated coverage on shares of Clorox in a research note on Friday, March 1st. They issued a sell rating and a $140.00 price objective on the stock. Five analysts have rated the stock with a sell rating and fourteen have issued a hold rating to the stock. According to MarketBeat, Clorox presently has an average rating of Hold and a consensus target price of $145.33.

Clorox Price Performance

Shares of CLX opened at $135.29 on Monday. The firm has a market cap of $16.80 billion, a PE ratio of 70.10, a PEG ratio of 2.15 and a beta of 0.39. The firm’s 50 day moving average price is $137.37 and its 200 day moving average price is $143.92. The company has a debt-to-equity ratio of 9.73, a quick ratio of 0.53 and a current ratio of 0.90. Clorox has a twelve month low of $114.68 and a twelve month high of $169.14.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.38. The firm had revenue of $1.81 billion for the quarter, compared to analyst estimates of $1.87 billion. Clorox had a net margin of 3.33% and a return on equity of 302.49%. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.51 earnings per share. As a group, research analysts expect that Clorox will post 5.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Clorox

Institutional investors and hedge funds have recently made changes to their positions in the company. Fortitude Family Office LLC acquired a new stake in shares of Clorox in the 4th quarter valued at $29,000. Venturi Wealth Management LLC boosted its stake in shares of Clorox by 308.5% in the 1st quarter. Venturi Wealth Management LLC now owns 192 shares of the company’s stock valued at $29,000 after purchasing an additional 145 shares in the last quarter. Northwest Financial Advisors acquired a new stake in shares of Clorox in the 4th quarter valued at $29,000. Core Wealth Advisors Inc. acquired a new stake in shares of Clorox in the 4th quarter valued at $29,000. Finally, First United Bank & Trust acquired a new stake in shares of Clorox in the 4th quarter valued at $31,000. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.